Biogen Idec Inc (BIIB) 423.57 $BIIB Pfizer's Cancer Drug

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 11:13 PM

Biogen Idec Inc (BIIB) 423.57 $BIIB

Pfizer's Cancer Drug Meets First Primary Endpoint in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 4:58PM CDT
Pfizer Inc.'s (PFE) phase III study on inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia (ALL) met the first primary endpoint.
BIIB: 423.57 (+1.46), PFE: 34.93 (+0.04), HZNP: 30.96 (+0.10), AMGN: 169.10 (+0.64)

15 'Sustainable' Companies Not Named Apple to Buy Right Now
at The Street - Wed Apr 22, 3:45PM CDT
American companies topped the list of global corporate sustainability leaders in 2015, but are they good investments? We take a look on earth day 2015.
KO: 41.31 (+0.53), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), GE: 26.91 (+0.29), A: 42.71 (-0.18), INTC: 32.70 (+0.27), ADBE: 75.50 (+0.88), JNJ: 100.43 (+0.13), SIAL: 138.92 (+0.17), CPB: 46.11 (+0.06), GIS: 56.21 (+0.10), CSCO: 28.62 (-0.07), CL: 69.28 (+0.27), ECL: 116.05 (+0.17), JCI: 51.33 (+0.30)

Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT

BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)

Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), IMMU: 4.14 (-0.04)

Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:30PM CDT
Agenus (AGEN) is expected to report first-quarter 2015 results on Apr 23.
AGEN: 6.08 (+0.21), BIIB: 423.57 (+1.46), INCY: 107.98 (-1.20), IMGN: 9.96 (+0.01)

The Fed And The Markets: Where To Invest In The Current Environment
Nicholas P. Cheer - at Seeking Alpha - Wed Apr 22, 1:08PM CDT

JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), BOND: 109.71 (-0.57), USB: 42.83 (+0.33), GILD: 104.18 (-1.02), AIG: 56.58 (-0.06), AAPL: 128.62 (+1.71), TLT: 127.72 (-1.98)

Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:02PM CDT
Alnylam Pharmaceuticals (ALNY) announced encouraging results from its phase II study on patisiran.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03)

Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)

Will Edwards Lifesciences (EW) Top Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:00PM CDT
The combination of Edwards' (EW) Zacks Rank #3 and +3.85% ESP makes us confident of a positive earnings beat at the company.
BIIB: 423.57 (+1.46), EW: 140.87 (+0.39), MRTX: 27.86 (-0.19), MEIP: 2.08 (-0.16)

Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth'
at The Street - Wed Apr 22, 9:18AM CDT
It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.
BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), AMGN: 169.10 (+0.64), CELG: 115.54 (+0.72)

Illumina (ILMN) Tops Q1 Earnings, Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:15AM CDT
Illumina (ILMN) has started off 2015 on a positive note with remarkable first-quarter results, which mark the 14th consecutive quarter of sequential revenue growth.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), CYTX: 0.96 (-0.09), ILMN: 190.04 (-9.27)

Actelion (ALIOF) Beats Q1 Earnings & Revenue Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:50AM CDT
Actelion Ltd. (ALIOF) reported first-quarter 2015 earnings of $1.57 per ADR beating the Zacks Consensus Estimate of $1.28 per ADR.
BIIB: 423.57 (+1.46), HZNP: 30.96 (+0.10), AMGN: 169.10 (+0.64)

The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Geron, Johnson & Johnson and Anthera Pharmaceuticals
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04)

Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 8:15AM CDT
Amgen (AMGN) started 2015 on a strong note with earnings and revenues surpassing expectations.
BIIB: 423.57 (+1.46), OSIR: 16.35 (-0.10), AMGN: 169.10 (+0.64), NVS: 103.45 (-0.62)

Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:00AM CDT
Perrigo Company's third-quarter fiscal 2015 earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.
BIIB: 423.57 (+1.46), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:54PM CDT
Pharmacyclics (PCYC) announced positive long-term follow-up data on Imbruvica.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91)

C. R. Bard (BCR) Q1 Earnings: Lutonix DCB Holds the Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:20PM CDT
C.R. Bard Inc. (BAX) is set to report first-quarter 2015 earnings results on Apr 23.
BSX: 18.41 (+0.10), BIIB: 423.57 (+1.46), BCR: 175.09 (+0.24), ATHN: 120.16 (-1.35)

Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:10PM CDT
Alexion Pharmaceuticals, Inc. is scheduled to report first-quarter 2015 earnings results on Apr 23 before the opening bell.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91)

Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Northern Jet Names Veteran Matthew Harris as CEO

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Cure Blindness Project's 770K Screenings for World Sight Day

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Skandia's Soundproofing Kit Expands to Brazil's Skies

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Navigating Holiday Sweets: Healthy Balancing Acts

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

NYSE Texas Redefines the U.S. Capital Markets Landscape

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

TA Services Strengthens U.S.-Mexico Freight Operations

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Epic Political Thriller Explores Humanity's Future

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...